Skip to Main Content

Advertisement

Current Issue
Volume 3,
Issue 23,
December 10, 2019

Advertisement


Blood Advances Editorial Fellowship Program for Early Career Faculty Members

Attention early career faculty members, contact Glenn Landis (glandis@hematoloy.org) to learn more about the Blood Advances Editorial Fellowship program.


Featured Content


American Society of Hematology 2019 guidelines for immune thrombocytopenia

The treatment of patients with immune thrombocytopenia continues to evolve with new understanding of the disease and treatment options. To address this need, the American Society of Hematology has developed new Guidelines pertaining to the treatment of this disorder that we hope is informative and helpful in your practice.


2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations

Treatment of patients with sickle cell disease (SCD) is challenging and often variable. The American Society of Hematology has convened a number of panels to address this challenge and develop treatment Guidelines that have undergone rigorous review and assessment of recommendations. In a review, the panel led by Murad and Mustafa describes the methodology, challenges, and innovations around the development of these Guidelines.


Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials

The discovery of molecular markers to identify patients at higher risk has been an important development in the treatment of a number of diseases. In patients with acute myelogenous leukemia, this has been particularly important. One example is the finding that patients with FLT3 mutations have a higher risk of relapse. The challenge of utilizing this information in clinical trial enrollment is highlighted in the Systematic Review by Borate and colleagues.


Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Heparin-induced thrombocytopenia (HIT) remains a significant clinical challenge, resulting in an increased risk of thrombosis. Activation of the platelet Fc receptor CD32a has been implicated as an early step in the pathogenesis in some patients. Siess and colleagues explored the role of Bruton tyrosine kinase inhibitors, which may present a new therapeutic option for this disorder.


The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

The development of biomarkers has been a significant advance in the diagnosis and prognosis of patients who are at risk for graft-vs-host disease following allogeneic hematopoietic stem cell transplantation. Now the MAGIC consortium of multiple sites in North America and Europe led by Ferrara utilized this approach in an attempt to predict outcome to therapy.


American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease

We are publishing the first set in a series of Guidelines pertaining to the treatment of patients with sickle cell disease (SCD). This set of Guidelines addresses cardiopulmonary and kidney disease. We hope this and future Guidelines help standardize treatment for patients with SCD.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement

X